AAM All Access Podcast - Dan Leonard speaks with Mary Beth Powers, President and CEO of CMMB.

Access! 2023 and 25th IGBA Conference

Two Conferences – One Location. Make plans to attend Access! 2023 and the 25th IGBA conference, February 13-16 in Orlando, Florida. Meet the leaders and decision-makers who are shaping the future of generics and biosimilars. Take advantage of the early bird promotion with $100 off each conference.

Register Now
Thanks for Joining us at GRx+Biosims!

A big thank you to all our sponsors, speakers and attendees who made #GRxBiosims 2022 a success. ICYMI, you can view the highlights on Twitter at #GRxBiosims. The GRx+Biosims conference took place November 7-9 in North Bethesda, Maryland.

View Twitter
2022 U.S. Generic & Biosimilar Medicines Savings Report

Savings continue to grow with $373B saved in 2021 the U.S. health care system, including patients, employers, and taxpayers. With 91% of Rx filled and only 18% of Rx drug spending, findings reinforce the critical importance of the generic and biosimilar industry to America’s patients.

Read Press Release
Explosive Growth in Drug Discount Cards is a Symptom of a Broken System

A new white paper from IQVIA shines light not only on the growth of these cards, but also on how much patients are unnecessarily spending on low-cost generic drugs.

Read Blog
AAM Voices of Access

Physicians, pharmacists, patients and caregivers across the country trust generics and biosimilars. Here are their stories, in their own words—along with perspectives from health care professionals and the AAM team.

View Report
Who’s Profiting from Your Prescription?

Unlike brand drugs where the manufacturer stands to profit the most, generic medicines are often exploited by middlemen that seize significant profits at the expense of patients and the companies that make the medicines.

Learn More

Working to leave a positive impact on...

Industry

We promote competition in the pharmaceutical industry by lowering barriers to entry for manufacturers of generic and biosimilar medicines and combatting anti-competitive abuses by some brand drug companies who put profits before patients. Learn More

People

We measure our success as an industry by the lives we impact. We work to protect the low cost of generic and biosimilar medicines and to drive down the cost of developing new ones, expanding access to as many people as possible. Learn More

Policy

We are a trusted partner and established authority within the pharmaceutical field. We provide accurate, timely data to educate policymakers and promote general public knowledge regarding the positive impact of affordable generic and biosimilar medicines. Learn More

About Us

The Association for Accessible Medicines improves access to safe, quality, effective medicine. Better access to medicine is relevant to everybody because, after all, we’re all patients at some point.

Health is the foundation for everything in life. Healthy people are better able to reach their full potential. Generics and biosimilars help more people in more places live healthier and longer.

Recent Updates

Medicare

Oct 19, 2022 | Monét Stanford

Patients Pay More When Generic Drugs Are Placed On Non-Generic Tiers, Even Though Prices For Generics Are Going Down

Meitheal Manufacturer

Oct 14, 2022 | Jewel Smith

Members Spotlight: Meitheal Pharmaceuticals

Video

Oct 14, 2022 | Erica Klinger

Join Us at Access! 2023

Closeup cashless wireless payment with credit card at the pharmacy

Oct 14, 2022 | Susan Reilly

AAM Statement on President Biden's Executive Order on Lowering Prescription Drug Costs

A young businesswoman delivering a speech during a conference

Oct 13, 2022 | Erica Klinger

How to Talk to Voters About the High Cost of Medicines and Ways to Lower Them

Oct 3, 2022 | Susan Reilly

AAM Statement on the Centers for Medicare & Medicaid Services’ Implementation of Medicare Part B Payment Changes for Biosimilars